Related Experiment Video

Updated: Jul 4, 2026

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Clarithromycin, montelukast, and pentoxifylline combination treatment ameliorates experimental neonatal hyperoxic

Korcan Demir1, Abdullah Kumral, Nuray Duman

  • 1Department of Pediatrics, Medical Faculty, Dokuz Eylul University, Inciralti, Izmir, Turkey.

The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
|June 24, 2008
PubMed

Insights

Combination therapy with clarithromycin, montelukast, and pentoxifylline effectively reduced hyperoxic lung injury in newborn rats. This approach shows promise for treating bronchopulmonary dysplasia.

Area of Science:

  • Neonatal medicine
  • Pulmonology
  • Pharmacology

Background:

  • Hyperoxic lung injury is a significant concern in neonates.
  • Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants, often resulting from prolonged oxygen exposure.
  • Current treatments for BPD lack definitive efficacy, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy of clarithromycin, montelukast, and pentoxifylline, individually and in combination, in mitigating histopathological signs of hyperoxic lung injury.
  • To determine if a combination therapy could offer superior protection against lung damage induced by hyperoxia in a neonatal rat model.

Main Methods:

  • Newborn rat pups (n=47) were divided into six groups: control (room air), hyperoxia with placebo, and hyperoxia with individual or combined drug treatments (clarithromycin, montelukast, pentoxifylline).
  • Exposure to hyperoxia (88-92% oxygen) occurred from postnatal days 3 to 13.
  • Histopathological assessments, including alveolar surface area, fibrosis, and smooth muscle actin expression, were performed on postnatal day 14.

Main Results:

  • Individual drug treatments did not show superiority over placebo in reducing lung injury markers.
  • The combination of clarithromycin, montelukast, and pentoxifylline significantly increased mean lung area percentage compared to placebo (64.0% vs. 50.2%, p=0.002).
  • Combination therapy also led to significantly lower smooth muscle actin scores (0 vs. 7, p=0.005), indicating reduced airway remodeling.

Conclusions:

  • Clarithromycin, montelukast, and pentoxifylline combination therapy is superior to placebo in a rat model of neonatal hyperoxic lung injury.
  • This combination therapy holds potential as an effective treatment strategy for bronchopulmonary dysplasia.
  • The findings suggest that targeting multiple pathways involved in BPD pathogenesis may be beneficial.
Abstract

More Related Videos

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice08:02

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice

Published on: October 19, 2013

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...